The Story of Hugh McLeod and an Interesting Case of McLeod Syndrome
The Kx antigen and, subsequently, the syndrome associated with loss of the antigen were discovered as a result of changes in antigenicity of the Kell blood group. McLeod syndrome (MLS) was first identified in an otherwise healthy 25-year-old male student at Harvard dental school, Hugh McLeod, through his novel Kell erythrocyte antigen profile, which was obtained as part of an unconsented screening survey undertaken in 1961 among incoming students. [1] [2] [3] McLeod's red blood cells manifested with evenly depressed Kell antigens and the loss of a public antigen, termed Kx. Initially, the Kx antigen was thought to be an antigen of the Kell blood group. The first description of antibody against the Kx antigen (anti-Kx) was published by Marsh et al 2 in 1975 in a study of young patients with chronic granulomatous disease and their relatives. The lack of Kx antigen was therefore linked to chronic granulomatous disease. However, the absence of chronic granulomatous disease symptoms in McLeod puzzled researchers because he also lacked Kx antigen on his red blood cells. We now understand that the reason for the absence of Kx antigen in McLeod was that his condition had a genetic basis that was considerably different from that of the patients in the survey by Marsh et al.
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McLeod continued his dental practice, despite progression of MLS symptoms, to the age of 64 years, and he died when he was 69 years of age. 4 The variant responsible for the McLeod phenotype was identified as a 13-base pair (bp) deletion at position 938-951intheXK gene (OMIM: 314850) that resulted in a premature stop at amino acid 336.
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Discovery of the XK Gene
The Kx antigen is encoded by the XK gene at the p21.1 region of the X chromosome (accession numbers: NG_007473.2 [genomic], NM _021083.3 [transcript] , LRG_812 [locus reference genomic identifier]). The XK gene spans a locus of 42 501 bp with 3 exons for a total coding region of 1335 bp, and the resulting mature protein has 444 amino acids. The chromosomal region associated with McLeod syndrome was located by comparative probe mapping of 10 samples from patients with MLS to a series of specifically defined clones spanning a region between the 2 loci known to cause Duchenne muscular dystrophy and chronic granulomatous disease. 6 The gene responsible for the McLeod phenotype was defined years later using radiolabeled cosmid probes, which uncovered a number of large nucleotide deletions in patients with MLS. The candidate gene was identified as XK and displayed a tissue distribution and expression pattern consistent with MLS.
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McLeod syndrome and chronic granulomatous disease were initially thought to be genetically linked, but we now know that the genes associated with chronic granulomatous disease (CYBB) (OMIM: 300481) and MLS (XK) are separate but in close proximity (<50 kbp apart) on the X chromosome. The deletion of all or part of both genes is often associated with a contiguous gene deletion syndrome, with larger deletions often involving genes associated with Duchenne muscular dystrophy (DMD) (OMIM: 300377) and retinitis pigmentosa (RPRG) (OMIM: 300110) . This finding indicates that the lack of Kx antigen and McLeod phenotype in the young patients with chronic granulomatous disease in the 1975 study by Marsh et al 2 was likely caused by contiguous gene deletion syndrome rather than specific genetic variants confined to the XK locus, as was the case for McLeod.
Serologic Presentation of Kx Antigen and MLS
Hematologic findings diagnostic for MLS are distinct and separate the presentation of MLS from that of other diseases under the neuroacanthocytosis umbrella. 8 The patient should present with an absence of Kx antigen and reduced expression of Kell blood group antigens demonstrated using a panel of human anti-Kx and monoclonal anti-Kell antibodies. This initial presentation facilitates a diagnostic algorithm for confirmatory testing of MLS. The presence of the KEL gene (OMIM: 613883) should be confirmed using polymerase chain reaction or other molecular methods to differentiate from the Kellnull phenotype. 9 The patient should be assessed for alloantibodies against the high-frequency antigen Kx, the high-frequency Kell antigen Km (also known as KEL20), and the presence of a compensated hemolytic state. The level of biochemical markers associated with hemolysis, such as lactate dehydrogenase and haptoglobin, should be determined, and serum creatine kinase levels, which are usually elevated in patients with MLS with concentrations reaching 4000 U/L (to convert to microkatals per liter, multiply by 0.0167), should also be determined. The presence of red blood cell acanthocytes should be confirmed using phase-contrast microscopy.
Neuroacanthocytosis and MLS
McLeod syndrome is part of the spectrum of neuroacanthocytosis syndromes, which are defined as progressive neurodegenerative diseases that affect mainly basal ganglia, including nucleus caudatus and putamen, in association with red blood cell anomalies, such as acanthocytosis. [8] [9] [10] [11] [12] Major representatives of neuroacanthocytosis sydromes with vastly overlapping clinical features are the autosomalrecessive choreoacanthocytosis (ChAc) and the X-linked MLS. Although panthothenate-kinase-associated neurodegeneration and Huntington disease-like disorder may rarely be associated with red blood cell acanthocytosis, these syndromes markedly differ from ChAc and MLS with respect to age of onset and mode of inheritance. Clinical features of the neuroacanthocytosis syndromes are outlined in the Table. Autosomal-recessive choreoacanthocytosis and MLS share many common phenotypic features, such as choreatic movement disorder, cognitive impairment and associated psychiatric disorders, seizures, and neuromuscular involvement with elevated creatine kinase levels, myopathy, and peripheral neuropathy associated with diminished or abolished deep-tendon reflexes.
10,13 These neuromuscular manifestations may widely differ in severity, ranging from isolated elevation of creatine kinase levels to disabling muscular weakness and atrophy. Because serum transaminase levels may also be elevated in patients with MLS, 14 patients have been misdiagnosed with hepatopathy. However, some patients with MLS have hepatosplenomegaly, most probably resulting from an increased red blood cell turnover caused by elevated red blood cell clearance in the context of the acanthocytic changes.
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Several neurologic manifestations in patients with ChAc, such as tongue and lip biting, tongue protrusion dystonia, head drops, parkinsonism, and truncal dystonia, were formerly believed to be specific for this disorder. However, recent reports describe these 
Phenotypic Variability
McLeod syndrome may exhibit a considerable phenotypic variability, even within the same family, with regard to the age at onset, the presenting symptoms, the development of additional symptoms, and the course of the disease. 18 In a series of patients with MLS, 3 had MLS detected as a result of donating blood, 3 presented with variable psychiatric disorders, 2 reported muscular weakness and atrophy or epileptic seizures, and only 1 had a choreatic movement disorder at the disease onset.
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Although the rarity of the disorder does not allow a conclusive genotype-phenotype correlation, available data suggest that missense mutations in the XK gene tend to lead to less pronounced neurologic and neuromuscular symptoms with a later onset than XK variants that cause truncation or nonexpression of the XK protein. 19, 20 This would be consistent with a residual physiologic activity in female carriers of XK missense mutations. 14, 21 However, all available clinical reports are consistent with a full penetrance of MLS in men, albeit possibly at an older age and possibly with nondisabling neurologic or neuromuscular symptoms. These considerations are important in the context of genetic counseling of patients with MLS and family members at risk of disease.
Clinical Diagnosis of MLS
The variable presentation of Xp21.1. mutations 18, 19, 22, 23 together with late onset of clinical symptoms make the diagnosis of MLS challenging. Diagnosis is almost exclusively restricted to male, middle-aged patients who exhibit a progressive chorea syndrome with the exclusion of other pathologies such as Huntington disease, Wilson disease, ChAc, and c9orf72-related disorders. 8, 24, 25 Neurologic presentation of symptoms is highly variable, although choreatic movement disorder; dystonia; cognitive impairment with premature dementia; psychiatric disorders including depression, bipolar disorder, and obsessive-compulsive disorder; and personality changes are common. 16, 17, 26 Areflexia or hyporeflexia are characteristic as are elevated creatine kinase levels and red blood cell abnormalities ranging from overt acanthocytosis to elevated rates of hyperchromic red blood cells in automated hematologic analysis. Serologic test results that indicate an absence of the Kx antigen are used to confirm diagnosis. Among blood donors with MLS, the absence of the Kx antigen may be recognized many years before clinical manifestation of symptoms and may even lead to an early diagnosis of MLS in asymptomatic blood donors. 3, 19 This is important to note for hematologists because this finding implies the probable development of neurologic and/or neuromuscular symptoms later in life and the necessity for neurogenetic counseling of these blood donors. In addition to mutations at the XK locus, large X-chromosomal deletions involving XK and its neighboring loci may lead to contigu- 
Women with Manifestations of MLS
As an X-linked neuroacanthocytosis syndrome, MLS is overwhelmingly confined to male patients. Lyonization (or X-inactivation) of the defective gene results in a normal phenotype or, rarely, weakened clinical presentation in women. It is possible that severe MLS in women could occur as the result of a compound heterozygosity, although to our knowledge, this is yet to be reported.
34
Of interest, in the only case of a woman with confirmed severe MLS to our knowledge, the proband was heterozygous for a 1-bp deletion in exon 2 in the XK gene (268delT terminating at AA129). It was shown that severely skewed lyonization resulted in inactivation of the normal XK gene in all tissues, including the brain. The patient developed seizures at 50 years of age, with gradual progression of neurologic symptoms including chorea and cognitive impairment before her death at 60 years of age.
14,21 Both of the patient's sons had MLS, with neurohematologic symptoms manifesting from their early to mid-20s before their deaths at the age of 31 years. The patient's sister and niece each exhibited mild neurologic symptoms (lower limb chorea and ankle areflexia) with variable presentation of Kell antigens, whereas the skew of lyonization ranged from slightly skewed in the sister to completely normal in the niece. Age-related skew of lyonization has been reported in female patients who present with progressive X-linked disorders, 35,36 which could explain the difference in skew between affected women. All family members with the variant, including heterozygotes, had hematologic profiles-acanthocytosis and elevated creatine kinase levels-that were consistent with MLS to varying degrees.
Biochemistry and Cell Biology of XK
In the red blood cell membrane, XK is a 10-transmembrane protein that forms a heterodimer with the Kell glycoprotein via the disulfide bond at XK Cys347 -Kell
Cys72
, as shown in Figure 1A . The XK-Kell dimer is part of the membrane multiprotein complex subunit 4.1, which also contains Band3 glycoprotein, glycophorin C, Rh protein/ Rh-associated glycoprotein, and Duffy protein 38 ( Figure 1B balance between the inner and outer red blood cell membrane leaflets leads to acanothcytic deformation of the red blood cell membrane. The absence of XK protein in the membrane leads to diminished levels of phosphatidylserine in the inner leaflet, which causes shrinkage of the membrane, interfering with transmembrane metabolite transport. 45, 46 In many nonerythroid tissues, the XK protein and Kell protein are expressed independently from each other, and in most tissue, including the brain and other neuronal tissue, only XK is translated. 47 The XK protein has been shown to have a pivotal role in organogenesis, cellular structure, and subcellular electrolyte and nutrient exchange, accounting for the multisystemic deficiency phenotype, which includes neurologic, neuropsychiatric, neuromuscular, and cardiologic manifestations. 4, 5, 48 As a matter of course, all manifestations attributable to XK alone may be drawn only from observations in (and experiments involving) individuals with mutations limited to the XK locus who do not exhibit a contiguous gene deletion syndrome.
Genetic Classification of XK Alleles and the Molecular Basis of MLS
The International Society of Blood Transfusion (ISBT) recognizes the XK protein and Kx antigen as an independent blood group system, defined as number 019 of the currently recognized 36 blood group systems. At present, the data described in the XK allele database comprise the most complete repository of variants with an associated McLeod phenotype. The Kx antigen, encoded by the native XK protein, is designated as the reference allele defined as XK*01. No other antigens have been defined in this system. The XK gene shows 8.2 variants per kilobase coding sequence, thereby ranking as one of the most conserved blood group genes, second only to Chido/Rodgers, encoded by C4A and C4B, with 5.5 and 4.4 variants per kilobase, respectively. 49 In addition to the variants described in the ISBT 
Review of the XK*N Allelic Variant Group
The majority of XK*N alleles consist of variants in 1 of the 3 exons or splice site loci of the XK gene. A summary of the XK allele variants derived from the ISBT database is presented in eTable 1 in the Supplement. The location of single-nucleotide variants and indels associated with the MLS phenotype are depicted in Figure 1C . 
Review of the XK*N.01 Series With Contiguous Gene Deletions
To date, 17 whole gene or contiguous gene deletions that include XK have been published (these are outlined in eTable 3 in the Supplement). Because of the molecular technologies available at the time that many of the older deletions were defined, breakpoints for these deletions are not precisely mapped. Given the rarity of whole gene deletions and contiguous gene deletions involving XK, the probability that the same deletion will be tabulated more than once is unlikely except in cases in which descent can be confirmed from familial studies. The suballeles are listed on the basis of the accuracy of locus and nucleotide discrimination: those that were characterized using older methods, such as microscopic examination or karyotyping and probe deletion analyses, 57,58 and those for which descriptions of deletions are determined with breakpoints to the nucleotide level. Figure 2 illustrates the range of the deletions associated with MLS and contiguous gene deletion syndromes for the 6 cases in which exact breakpoints are defined. Whole genome sequencing now allows researchers to more easily determine the nucleotide breakpoints involved in contiguous gene deletion syndrome and MLS. In addition, polymerase chain reaction and Sanger sequencing targeting splice site and exonic regions or stepwise partitioned polymerase chain reaction analysis of XK and flanking regions are still used for the discovery of mutations responsible for the McLeod blood group phenotype. 27, 59 In the case of XK deletions, the stepwise partitioning method can be used to determine exact nucleotide breakpoints without the requirement for whole genome sequencing. 27 With the introduction of third- Recent studies have demonstrated promising results with the use of nonhomologous end-joining recombination using RNAguided CRISPR/Cas9 nucleases in repairing short indel and frameshift variations in the chronic granulomatous disease gene CYBB, with less success in repairing single-nucleotide variants leading to nonsense and missense mutations. Although the technology is still in its infancy, these therapies may be directly translatable to other monogenic hematopoetic blood disorders, such as MLS. 63, 64 In addition, the use of targeted insertion of therapeutic transgenes into defined viral integration sites will allow for alteration of the patient's own stem cells for transplantation. 65 Of note, the morphologically, functionally, and structurally altered red blood cells in XK mutation carriers may provide an easily accessible cellular substrate to determine the pathobiologic features of Xp21.1 mutations and to discover new potential therapeutic strategies for improvement of multisystem manifestations of MLS.
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Conclusions
McLeod syndrome is a progressive, debilitating X-linked neurohematologic disorder that is caused by variation in the XK gene, resulting in truncation of the mature XK protein or changes in transmembrane conformation and structure within the red blood cell membrane and other tissues. McLeod syndrome can also present as part of a contiguous gene deletion syndrome caused by a whole or partial gene deletion, including deletion of adjacent genes such as CYBB, DMD, and RPGR. It can occur in individuals 20 years of age or older, whereas neurologic, neuromuscular, and cardiologic manifestations vary widely and occur late in a patient's life. Information on the molecular basis of MLS and associated gene deletion syndromes has previously been diffuse and widely distributed. We collected and elaborated on the molecular basis of MLS to provide a reference base for clinicians. 
